Sign in
Taking people in United StatesNo phase

Tests an automated insulin system for type 1 diabetes in adults

Tests a device that delivers insulin automatically in adults with type 1 diabetes.

Key facts

Who runs it
Oregon Health and Science University
Where
Portland, United StatesSee the site
Trial code
Registry title
Closed Loop Context Aware AID
Status
Recruiting
People taking part
10 people, planned
Started
22 Nov 2024
Planned end
30 Aug 2025
Type of study
Interventional
Treatments tested
  • iPancreas automated insulin delivery system
Record updated
11 April 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 1 diabetes who already use a hybrid closed loop insulin system. It tests a new high blood sugar detection and dosing algorithm.

Age
18 years and older (up to 100 years)
Sex
All sexes can join.
Disease stage
Type 1 diabetes for at least 1 year, with HbA1c or GMI of 7.0% (53 mmol/mol) or higher at screening.
Earlier treatment
Must have used an FDA-approved hybrid closed loop system for 3 months or more. Total daily insulin must be less than 139 units/day.
Biomarker or test result
HbA1c or GMI of 7.0% (53 mmol/mol) or higher at screening. GMI or A1c must not be below 6.5% (48 mmol/mol) or above 10.5% (91 mmol/mol).

Main reasons for not taking part

  • Pregnant, planning pregnancy or breast-feeding
  • Any cardiovascular disease, or kidney (GFR < 60 ml/min) or liver disease
  • Severe low blood sugar or diabetic ketoacidosis in the past 6 months
  • Use of corticosteroids, beta blockers, or glucose-lowering drugs other than insulin (metformin only if the dose is stable)
  • Allergy to Fiasp insulin

The registry criteria, word for word

Show all 40 criteriaShow less

Who can take part

  • Diagnosis of type 1 diabetes mellitus for at least 1 year
  • Male or female participants 18 and older
  • HbA1c or GMI ≥ 7.0% at screening
  • Physically willing and able to perform 30 min of exercise (as determined by the investigator after reviewing the participant's activity level)
  • Current use of an FDA-approved hybrid closed loop system for ≥3 months
  • Lives with another person age 18 or older who will sleep in the house at night and that can attend the training on using the system
  • Lives within 40 miles of OHSU
  • Total daily insulin requirement is less than 139 units/day
  • Able to read, write and understand spoken English
  • Current use of a smartphone so can be contacted by study staff off-campus
  • Willingness to follow all study procedures, including attending all clinic visits
  • Willingness to sign informed consent and HIPAA documents

Who cannot take part

  • History of severe hypoglycemia during the past 6 months prior to screening visit or hypoglycemia unawareness as judged by the investigator. Participants will complete a hypoglycemia awareness questionnaire. Participants will be excluded for four or more R responses
  • History of diabetes ketoacidosis during the prior 6 months prior to screening visit, as diagnosed on hospital admission or as judged by the investigator
  • Known or suspected abuse of alcohol, narcotics, or illicit drugs
  • Major surgical operation within 30 days prior to screening
  • Use of an investigational drug within 30 days prior to screening
  • Chronic usage of any immunosuppressive medication (such as cyclosporine, azathioprine, sirolimus, or tacrolimus)
  • Current administration of oral or parenteral corticosteroids
  • Any cardiovascular disease, defined as a clinically significant EKG abnormality at the time of screening or any history of: stroke, heart failure, myocardial infarction, angina pectoris, or coronary arterial bypass graft or angioplasty. Diagnosis of 2nd or 3rd degree heart block or any non-physiological arrhythmia judged by the investigator to be exclusionary
  • Liver failure, cirrhosis, or any other liver disease that compromises liver function as determined by the investigator
  • Adrenal insufficiency
  • Any active infection (example skin infection requiring antibiotics)
  • Seizure disorder
  • Peripheral arterial disease
  • Allergy to Fiasp insulin
  • Any life threatening disease, including malignant neoplasms and medical history of malignant neoplasms within the past 5 years prior to screening (except basal and squamous cell skin cancer)
  • A positive response to any of the questions from the Physical Activity Readiness Questionnaire with one exception: participant will not be excluded if he/she takes a single blood pressure medication that doesn't impact heart rate and blood pressure is controlled on the medication (blood pressure is less than 140/90 mmHg)
  • Any clinically significant disease or disorder which in the opinion of the Investigator may jeopardize the participant's safety or compliance with the protocol
  • Sensor glucose shows < 2% of time above 250 mg/dl in last 30 days
  • Renal insufficiency (GFR < 60 ml/min, using the MDRD equation as reported by the OHSU laboratory)
  • Bleeding disorder or platelet count below 50,000
  • Use of beta blockers or non-dihydropyridine calcium channel blockers
  • Current use of any medication that can lower glucose other than insulin (ex. Wegovy, Jardiance) with the exception of metformin if dose has been stable for ≥3 months and patient willing to not change dose during study
  • GMI or A1c <6.5% or >10.5%
  • Individual of childbearing potential who is pregnant or intending to become pregnant or breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence
  • Active foot ulceration
  • Gastroparesis
  • Diet consisting of less than 50 grams of carbohydrates per day
  • Any chest discomfort with physical activity, including pain or pressure, or other types of discomfort

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

Where in United States

  • Oregon Health and Science UniversityPortland, United StatesContact: Leah Wilson, MDTaking people

About the trial

What the trial wants to find out

An artificial pancreas (AP) is a control system for automatic insulin delivery. The investigators have implemented a high blood sugar detection and dosing algorithm for use within an AP control system. If a high blood sugar pattern is detected, correction insulin will be calculated and delivered. The investigators will test how well the new algorithm manages glucose compared to the AP control system without high blood sugar detection and dosing. This type of algorithm may improve glucose control for high risk patient populations.

The group in the trial

  • iPancreas automated insulin delivery systemTreatment being tested

    Participants will use the iPancreas automated insulin delivery system for 4 weeks at home. After 3 weeks of collecting high blood sugar pattern data, the high blood sugar pattern detection and dosing feature will be turned on.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessment of a Fully-closed Loop AID System With a Context-aware Hyperglycemia Pattern Detection and Dosing Algorithm in People With Type 1 Diabetes
Plain-language title
Tests an automated insulin system for type 1 diabetes in adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06676657, who can take part
Record updated
11 April 2025